A systematic review and meta-analysis of 11 studies (2,039 patients) found that NOTCH1 mutations are associated with significantly improved event-free survival in T-ALL patients (RR 0.63, 95% CI: 0.51–0.78), supporting their use as a prognostic biomarker.